MetaCap

Phio Pharmaceuticals Corp. (PHIO)

NASDAQ: PHIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.656-0.059 (-8.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PHIO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.21
52-week range
0.6395 – 1.88
Day range
0.6395 – 0.7308
Volume / Avg
145.41K / 106.09K
Beta
—

52-week range

$0.6395$1.88

PHIO stock today

On Nov 20, PHIO ended the session at $0.656, shedding $0.059 (8.25%), versus the S&P 500's 3.70% decline. At this level, PHIO sits near the bottom of its 52-week range of $0.6395 to $1.88: 65.1% below the high, set on Feb 13, 2026 and 2.6% above the low. PHIO is down 37.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 41.4%.

Phio Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.21), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Phio Pharmaceuticals

Company profile

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Robert J. Bitterman
Headquarters
King of Prussia, PA
Employees
6

Financial highlights

Full financials

Phio Pharmaceuticals reported a net loss of $8.7 million, compared with a loss of $7.2 million a year earlier.

Phio Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-8.70M$-7.15M$-10.83M$-11.48M$-13.29M
EPS (diluted)—$-9.08$-46.76$-10.10$-12.43

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$14.00+2034.15%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.36 vs $-0.36

PHIO news

All PHIO news

Phio Pharmaceuticals peers

Health Care sector
PHIO peer companies
CompanyPrice% ChgMarket capCompare
CLRBCellectar Biosciences Inc.0.797-11.50%$8.00Mvs PHIO
DAREDare Bioscience Inc.0.4074-9.87%$8.01Mvs PHIO
VTGNVistagen Therapeutics Inc.0.1636-12.33%$7.56Mvs PHIO
PTNPalatin Technologies Inc.4.58-7.10%$8.16Mvs PHIO
MBRXMoleculin Biotech Inc.7.74-2.40%$8.22Mvs PHIO
RKTORocket One Inc.0.297+5.24%$7.39Mvs PHIO
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares1.29-9.15%$8.29Mvs PHIO
IMRNImmuron Limited ADR0.8998+5.80%$7.26Mvs PHIO

Indexes, lists and sector

Phio Pharmaceuticals stock FAQ

What is Phio Pharmaceuticals's stock price today?

PHIO last traded at $0.656 as of Nov 20, 4:00 PM EST, down 8.25% on the day. Prices are delayed at least 15 minutes.

Does Phio Pharmaceuticals pay a dividend?

No. Phio Pharmaceuticals does not currently pay a regular cash dividend.

Who is Phio Pharmaceuticals's CEO?

Mr. Robert J. Bitterman is the chief executive officer of Phio Pharmaceuticals Corp., which has about 6 employees.

Has PHIO ever split its stock?

Yes. The most recent PHIO stock split was a 1-for-9 split on Jul 5, 2024, one of 6 splits on record.

What is the PHIO 52-week high?

The 52-week high for PHIO is $1.88 and the 52-week low is $0.6395. The stock is currently 65.1% below its high.

Compare PHIO